On October 28, 2019 Apexian Pharmaceuticals, Inc., a clinical stage drug development company focused on advancing APX3330 for the treatment of diseases mediated by the APE1/Ref-1 protein, reported additional data on their Phase 1 study using APX3330 in patients with advanced solid tumors (Press release, Apexian Pharmaceuticals, OCT 28, 2019, View Source [SID1234549919]). Results of the trial were presented as a talk in the "Spotlight on Proffered Papers: Emerging Data from Phase I Trials of New Molecular Entities" session on Sunday, October 27.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
An additional presentation followed in a poster session. The presentations occurred at the American Association for Cancer Research (AACR) (Free AACR Whitepaper)-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) (Free AACR-NCI-EORTC Whitepaper) annual international meeting in Boston, MA. The presentation titled "A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor" was presented by Dr. Mark R. Kelley, Chief Scientific Officer of Apexian and Professor of Pediatrics, Indiana University Simon Cancer Center.
"As we continue development of APX3330 for cancer and other indications, we are very pleased to have been selected to present our phase I trial findings in a platform talk and poster presentation" said Dr. Mark Kelley, Chief Scientific Officer of Apexian. "APX3330 is an oral drug and we observed a strong safety profile, recommended phase 2 dose, predicted PK and target engagement of APX3330 on APE1/Ref-1 using transcriptome and proteomic analysis of tumors".
Dr. Richard Messmann, Chief Medical Officer of Apexian added, "The APE1/Ref-1 protein plays a critical role in mediating a variety of diseases. Our phase I data have now confirmed that APX3330 targets the APE1 protein as expected. These findings pave the way toward confirming the utility of APX3330 in treating diseases as diverse as cancer, diabetic retinopathy, and inflammatory bowel disease, all mediated by the APE1/Ref-1 protein."